Skye Bioscience (SKYE) Competitors $4.07 -0.18 (-4.24%) Closing price 04:00 PM EasternExtended Trading$4.12 +0.05 (+1.35%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE vs. OLMA, RGNX, AQST, CMPS, CYRX, BCYC, ARCT, CMPX, ETON, and EOLSShould you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Olema Pharmaceuticals (OLMA), REGENXBIO (RGNX), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), CryoPort (CYRX), Bicycle Therapeutics (BCYC), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Eton Pharmaceuticals (ETON), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Skye Bioscience vs. Its Competitors Olema Pharmaceuticals REGENXBIO Aquestive Therapeutics COMPASS Pathways CryoPort Bicycle Therapeutics Arcturus Therapeutics Compass Therapeutics Eton Pharmaceuticals Evolus Skye Bioscience (NASDAQ:SKYE) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Do analysts prefer SKYE or OLMA? Skye Bioscience presently has a consensus target price of $15.50, indicating a potential upside of 280.84%. Olema Pharmaceuticals has a consensus target price of $24.00, indicating a potential upside of 200.00%. Given Skye Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Skye Bioscience is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Olema Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do insiders & institutionals have more ownership in SKYE or OLMA? 21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 3.0% of Skye Bioscience shares are owned by company insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor SKYE or OLMA? In the previous week, Olema Pharmaceuticals had 6 more articles in the media than Skye Bioscience. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 4 mentions for Skye Bioscience. Olema Pharmaceuticals' average media sentiment score of 1.27 beat Skye Bioscience's score of 0.70 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SKYE or OLMA more profitable? Olema Pharmaceuticals' return on equity of -42.58% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -76.03% -69.20% Olema Pharmaceuticals N/A -42.58%-38.65% Which has more risk and volatility, SKYE or OLMA? Skye Bioscience has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Which has higher valuation and earnings, SKYE or OLMA? Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$26.57M-$1.06-3.84Olema PharmaceuticalsN/AN/A-$129.47M-$1.98-4.04 SummarySkye Bioscience beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition Export to ExcelMetricSkye BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.13M$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-3.8421.3874.9226.41Price / SalesN/A243.79457.0188.61Price / CashN/A44.4425.8129.91Price / Book1.819.6413.256.28Net Income-$26.57M-$53.20M$3.29B$270.38M7 Day Performance-1.21%0.44%0.47%2.70%1 Month Performance15.95%4.26%4.59%5.99%1 Year Performance-32.17%9.43%73.41%25.94% Skye Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience2.0613 of 5 stars$4.07-4.2%$15.50+280.8%-29.2%$126.13MN/A-3.8411OLMAOlema Pharmaceuticals2.8584 of 5 stars$7.44-1.8%$24.00+222.6%-38.8%$510.61MN/A-3.7670Positive NewsRGNXREGENXBIO4.5906 of 5 stars$9.89+4.3%$28.38+186.9%-28.3%$499.58M$155.78M-2.87370AQSTAquestive Therapeutics2.2023 of 5 stars$4.98-0.6%$10.29+106.5%+4.3%$496.61M$57.56M-7.11160CMPSCOMPASS Pathways3.2481 of 5 stars$5.17+3.8%$16.29+215.0%-28.3%$496.01MN/A-2.81120Positive NewsCYRXCryoPort3.844 of 5 stars$9.85-1.9%$12.00+21.8%+3.5%$493.16M$237.88M7.411,186Positive NewsInsider TradeBCYCBicycle Therapeutics3.1085 of 5 stars$7.12+1.7%$22.22+212.1%-73.8%$493.06M$35.28M-2.03240Positive NewsARCTArcturus Therapeutics3.0343 of 5 stars$17.94+0.6%$50.57+181.9%-16.5%$487.16M$109.80M-8.04180Positive NewsCMPXCompass Therapeutics2.384 of 5 stars$3.48+1.2%$12.89+270.4%+116.4%$481.21M$850K-7.7320ETONEton Pharmaceuticals2.2873 of 5 stars$17.85+0.4%$29.67+66.2%+242.7%$478.74M$39.01M-111.5620News CoveragePositive NewsEOLSEvolus4.0655 of 5 stars$7.39-2.9%$21.25+187.6%-58.9%$478.02M$277.94M-7.54170Positive News Related Companies and Tools Related Companies OLMA Alternatives RGNX Alternatives AQST Alternatives CMPS Alternatives CYRX Alternatives BCYC Alternatives ARCT Alternatives CMPX Alternatives ETON Alternatives EOLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SKYE) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SKYE Stock Alerts